MNA-001 / Muna Therap - LARVOL DELTA

Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer’s Disease (PRNewswire) - "Phase 1 study initiated to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects of MNA-001 on biomarkers of TREM2 target engagement and activation, with topline data expected mid 2026."

P1 data • Trial status • Alzheimer's Disease